Videos

Kidney Week 2026 registry data linked a selective cytopheretic device to higher survival in children with septic AKI requiring CRRT.

Rami Kahwash discusses his presentation at HFSA 2026, which highlighted the real-world efficacy of cardiac contractility modulation therapy.

Aaron Farberg, MD, discusses gene expression testing in atopic dermatitis and melanoma, Ameluz PDT for basal cell carcinoma, and the psoriasis pipeline.

Rohit Gupta, MD, discusses advanced pulmonary sarcoidosis, antifibrotic uncertainty, and first-line methotrexate data after a CHEST 2026 session.

Marla Dubinsky, MD, discusses phase 3 SHINE-2 data showing mirikizumab induced clinical remission in 41.3% of children with UC by week 12.

Jennifer Hsiao, MD, shares how she sets expectations, selects and reassesses biologics, and screens for comorbidities in patients with hidradenitis suppurativa.

Lawrence Eichenfield, MD, discusses phase 2 data showing nemolizumab improved itch, sleep, and quality of life in children 2 to 11 with atopic dermatitis.

James Chalmers, MBChB, PhD, discusses an ASPEN post hoc analysis linking sputum color to neutrophil serine protease activity at CHEST 2026.

Emmanuel Montassier presented potassium data at 60 minutes from 398 adults treated for acute hyperkalemia in the ED.

On World Psoriasis Day, advocates Nitika Chopra and Ayesha Patrick share how dermatologists can better support women of color living with visible psoriasis.

Patients with IPF reported less severe, less frequent cough within 2 weeks of nalbuphine ER in CORAL, with gains sustained through week 6.

Investigators will probe acid base metabolism and metabolomics to explain the blood pressure and potassium findings from DapaBalci-Leap.

David Leehey, MD, says about half of the 2376 enrolled veterans were taking an SGLT2 inhibitor at baseline.

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

An early behavioral activation therapy signal at 8 weeks didn’t hold, and bupropion brought more insomnia and confusion.

Michael Pritchett, DO, MPH, discusses real-world Ion Registry yield, sensitivity, and safety data for robotic bronchoscopy presented at CHEST 2026.

In interim V012 data, women on hemodialysis reached usable access months sooner with ATEV, said Prabir Roy-Chaudhury, MD, PhD.

Prabir Roy-Chaudhury, MD, PhD, explains how the ATEV is made and the research questions he wants answered next.

AI models have not outperformed existing clinical scores for COPD prognosis, but home monitoring may help track disease activity, Bourbeau said.

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

A retrospective cohort of 34,398 veterans found similar hospital days in VA and community dialysis settings across pandemic periods.

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Balcinrenone lowered systolic BP by 14.1 mm Hg in stage 3 CKD, while combination therapy preserved dapagliflozin's glucosuric effect.

James Tumlin, MD, discusses RAINIER's proteinuria findings, dual APRIL/BAFF inhibition, safety, and the upcoming FDA decision.

Longer GLP-1 RA exposure was also associated with a lower hospitalization burden in a cohort of 5,897 patients with type 2 diabetes.

A Kidney Week 2026 survey examines why patients miss dialysis, when barriers arise, and how outreach relates to rescheduling.